No Data
No Data
Aldeyra Therapeutics: A Buy Rating on Strong Clinical Progress and Market Potential
Express News | Aldeyra Therapeutics Inc : Jefferies Raises Target Price to $8 From $7
Buy Recommendation for Aldeyra Therapeutics Amid Positive Phase 3 Results for Reproxalap
Aldeyra Therapeutics Shares Rise 9.2% on Trial Outcome for Dry Eye Disease Treatment
Express News | Aldeyra Therapeutics Achieves Primary Endpoint In Phase 3 Trial For Reproxalap Ophthalmic Solution In Treating Dry Eye Disease; Statistically Superior For Ocular Discomfort; NDA Resubmission Anticipated In 2024
Express News | Aldeyra: No Safety Signals Observed in Clinical Trial, and Reproxalap Was Observed to Be Well Tolerated
No Data